{"id":1295,"date":"2013-12-03T04:16:21","date_gmt":"2013-12-03T04:16:21","guid":{"rendered":"http:\/\/wpexplorer-demos.com\/?page_id=1295"},"modified":"2023-03-12T02:18:31","modified_gmt":"2023-03-12T02:18:31","slug":"product-pipeline","status":"publish","type":"page","link":"https:\/\/glycomantra.com\/sample\/product-pipeline\/","title":{"rendered":"Product Pipeline"},"content":{"rendered":"<section class=\"wpb-content-wrapper\">[vc_row css_animation=&#8221;appear&#8221; center_row=&#8221;yes&#8221; bg_style=&#8221;stretch&#8221; video_bg_overlay=&#8221;none&#8221; css=&#8221;.vc_custom_1622132688347{padding-top: 0px !important;padding-bottom: 0px !important;}&#8221;][vc_column][vc_column_text]\n<h1><span style=\"color: #2684c4;\"><strong>Multi-Indication Assets<\/strong><\/span><\/h1>\n<p>GlycoMantra has developed a few high-affinity galectin-3 antagonists (GM100 series) useful for various indications (see <strong>Drug Pipeline<\/strong>). GlycoMantra\u2019s CAR-T asset is based on a novel concept of personalized \u201coff-the-shelf\u201d cellular immunotherapy for kidney cancer. GlycoMantra\u2019s other asset is small molecule drug for metastatic colorectal cancer.<\/p>\n<p><a href=\"https:\/\/glycomantra.com\/sample\/wp-content\/uploads\/2022\/02\/Pipeline-Figure-Updated-01-27-22.jpg\"><img decoding=\"async\" loading=\"lazy\" class=\"alignnone size-full wp-image-4135\" src=\"https:\/\/glycomantra.com\/sample\/wp-content\/uploads\/2022\/02\/Pipeline-Figure-Updated-01-27-22.jpg\" alt=\"Glycomantra Drug Pipeline\" width=\"720\" height=\"405\" srcset=\"https:\/\/glycomantra.com\/sample\/wp-content\/uploads\/2022\/02\/Pipeline-Figure-Updated-01-27-22.jpg 720w, https:\/\/glycomantra.com\/sample\/wp-content\/uploads\/2022\/02\/Pipeline-Figure-Updated-01-27-22-300x169.jpg 300w\" sizes=\"(max-width: 720px) 100vw, 720px\" \/><\/a>[\/vc_column_text]<div class=\"vcex-spacing wpex-w-100 wpex-clear\"><\/div><div class=\"theme-button-wrap textcenter theme-button-block-wrap wpex-block wpex-clear wpex-clr\"><a href=\"http:\/\/www.glycorx.com\/?page_id=3530\" class=\"vcex-button theme-button graphical blue large align-center block  wpb_animate_when_almost_visible wpb_appear appear\" style=\"border-radius:3px;\" title=\"Contact Us\" rel=\"none\"><span class=\"vcex-button-inner theme-button-inner\">Contact us<\/span><\/a><\/div> [\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row]\n<\/section>","protected":false},"excerpt":{"rendered":"<p>[vc_row css_animation=&#8221;appear&#8221; center_row=&#8221;yes&#8221; bg_style=&#8221;stretch&#8221; video_bg_overlay=&#8221;none&#8221; css=&#8221;.vc_custom_1622132688347{padding-top: 0px !important;padding-bottom: 0px !important;}&#8221;][vc_column][vc_column_text] Multi-Indication Assets GlycoMantra has developed a few high-affinity galectin-3 antagonists (GM100 series) useful for various indications (see Drug Pipeline). GlycoMantra\u2019s CAR-T asset is based on a novel concept of personalized \u201coff-the-shelf\u201d cellular immunotherapy for kidney cancer. GlycoMantra\u2019s other asset is small molecule drug for metastatic&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Product Pipeline - https:\/\/glycomantra.com\/sample<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/glycomantra.com\/sample\/product-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Product Pipeline - https:\/\/glycomantra.com\/sample\" \/>\n<meta property=\"og:description\" content=\"[vc_row css_animation=&#8221;appear&#8221; center_row=&#8221;yes&#8221; bg_style=&#8221;stretch&#8221; video_bg_overlay=&#8221;none&#8221; css=&#8221;.vc_custom_1622132688347{padding-top: 0px !important;padding-bottom: 0px !important;}&#8221;][vc_column][vc_column_text] Multi-Indication Assets GlycoMantra has developed a few high-affinity galectin-3 antagonists (GM100 series) useful for various indications (see Drug Pipeline). GlycoMantra\u2019s CAR-T asset is based on a novel concept of personalized \u201coff-the-shelf\u201d cellular immunotherapy for kidney cancer. GlycoMantra\u2019s other asset is small molecule drug for metastatic&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/glycomantra.com\/sample\/product-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"https:\/\/glycomantra.com\/sample\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-12T02:18:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/glycomantra.com\/sample\/wp-content\/uploads\/2022\/02\/Pipeline-Figure-Updated-01-27-22.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/glycomantra.com\/sample\/product-pipeline\/\",\"url\":\"https:\/\/glycomantra.com\/sample\/product-pipeline\/\",\"name\":\"Product Pipeline - https:\/\/glycomantra.com\/sample\",\"isPartOf\":{\"@id\":\"https:\/\/glycomantra.com\/sample\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/glycomantra.com\/sample\/product-pipeline\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/glycomantra.com\/sample\/product-pipeline\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/glycomantra.com\/sample\/wp-content\/uploads\/2022\/02\/Pipeline-Figure-Updated-01-27-22.jpg\",\"datePublished\":\"2013-12-03T04:16:21+00:00\",\"dateModified\":\"2023-03-12T02:18:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/glycomantra.com\/sample\/product-pipeline\/#breadcrumb\"},\"inLanguage\":\"en\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/glycomantra.com\/sample\/product-pipeline\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en\",\"@id\":\"https:\/\/glycomantra.com\/sample\/product-pipeline\/#primaryimage\",\"url\":\"https:\/\/glycomantra.com\/sample\/wp-content\/uploads\/2022\/02\/Pipeline-Figure-Updated-01-27-22.jpg\",\"contentUrl\":\"https:\/\/glycomantra.com\/sample\/wp-content\/uploads\/2022\/02\/Pipeline-Figure-Updated-01-27-22.jpg\",\"width\":720,\"height\":405,\"caption\":\"Glycomantra Drug Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/glycomantra.com\/sample\/product-pipeline\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/glycomantra.com\/sample\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Product Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/glycomantra.com\/sample\/#website\",\"url\":\"https:\/\/glycomantra.com\/sample\/\",\"name\":\"https:\/\/glycomantra.com\/sample\",\"description\":\"Glycomantra\",\"publisher\":{\"@id\":\"https:\/\/glycomantra.com\/sample\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/glycomantra.com\/sample\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/glycomantra.com\/sample\/#organization\",\"name\":\"Glycomantra\",\"url\":\"https:\/\/glycomantra.com\/sample\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en\",\"@id\":\"https:\/\/glycomantra.com\/sample\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/www.glycorx.com\/wp-content\/uploads\/2014\/03\/final-logo-72.png\",\"contentUrl\":\"http:\/\/www.glycorx.com\/wp-content\/uploads\/2014\/03\/final-logo-72.png\",\"width\":72,\"height\":72,\"caption\":\"Glycomantra\"},\"image\":{\"@id\":\"https:\/\/glycomantra.com\/sample\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Product Pipeline - https:\/\/glycomantra.com\/sample","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/glycomantra.com\/sample\/product-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Product Pipeline - https:\/\/glycomantra.com\/sample","og_description":"[vc_row css_animation=&#8221;appear&#8221; center_row=&#8221;yes&#8221; bg_style=&#8221;stretch&#8221; video_bg_overlay=&#8221;none&#8221; css=&#8221;.vc_custom_1622132688347{padding-top: 0px !important;padding-bottom: 0px !important;}&#8221;][vc_column][vc_column_text] Multi-Indication Assets GlycoMantra has developed a few high-affinity galectin-3 antagonists (GM100 series) useful for various indications (see Drug Pipeline). GlycoMantra\u2019s CAR-T asset is based on a novel concept of personalized \u201coff-the-shelf\u201d cellular immunotherapy for kidney cancer. GlycoMantra\u2019s other asset is small molecule drug for metastatic&hellip;","og_url":"https:\/\/glycomantra.com\/sample\/product-pipeline\/","og_site_name":"https:\/\/glycomantra.com\/sample","article_modified_time":"2023-03-12T02:18:31+00:00","og_image":[{"url":"https:\/\/glycomantra.com\/sample\/wp-content\/uploads\/2022\/02\/Pipeline-Figure-Updated-01-27-22.jpg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/glycomantra.com\/sample\/product-pipeline\/","url":"https:\/\/glycomantra.com\/sample\/product-pipeline\/","name":"Product Pipeline - https:\/\/glycomantra.com\/sample","isPartOf":{"@id":"https:\/\/glycomantra.com\/sample\/#website"},"primaryImageOfPage":{"@id":"https:\/\/glycomantra.com\/sample\/product-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/glycomantra.com\/sample\/product-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/glycomantra.com\/sample\/wp-content\/uploads\/2022\/02\/Pipeline-Figure-Updated-01-27-22.jpg","datePublished":"2013-12-03T04:16:21+00:00","dateModified":"2023-03-12T02:18:31+00:00","breadcrumb":{"@id":"https:\/\/glycomantra.com\/sample\/product-pipeline\/#breadcrumb"},"inLanguage":"en","potentialAction":[{"@type":"ReadAction","target":["https:\/\/glycomantra.com\/sample\/product-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en","@id":"https:\/\/glycomantra.com\/sample\/product-pipeline\/#primaryimage","url":"https:\/\/glycomantra.com\/sample\/wp-content\/uploads\/2022\/02\/Pipeline-Figure-Updated-01-27-22.jpg","contentUrl":"https:\/\/glycomantra.com\/sample\/wp-content\/uploads\/2022\/02\/Pipeline-Figure-Updated-01-27-22.jpg","width":720,"height":405,"caption":"Glycomantra Drug Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/glycomantra.com\/sample\/product-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/glycomantra.com\/sample\/"},{"@type":"ListItem","position":2,"name":"Product Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/glycomantra.com\/sample\/#website","url":"https:\/\/glycomantra.com\/sample\/","name":"https:\/\/glycomantra.com\/sample","description":"Glycomantra","publisher":{"@id":"https:\/\/glycomantra.com\/sample\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/glycomantra.com\/sample\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en"},{"@type":"Organization","@id":"https:\/\/glycomantra.com\/sample\/#organization","name":"Glycomantra","url":"https:\/\/glycomantra.com\/sample\/","logo":{"@type":"ImageObject","inLanguage":"en","@id":"https:\/\/glycomantra.com\/sample\/#\/schema\/logo\/image\/","url":"http:\/\/www.glycorx.com\/wp-content\/uploads\/2014\/03\/final-logo-72.png","contentUrl":"http:\/\/www.glycorx.com\/wp-content\/uploads\/2014\/03\/final-logo-72.png","width":72,"height":72,"caption":"Glycomantra"},"image":{"@id":"https:\/\/glycomantra.com\/sample\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/glycomantra.com\/sample\/wp-json\/wp\/v2\/pages\/1295"}],"collection":[{"href":"https:\/\/glycomantra.com\/sample\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/glycomantra.com\/sample\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/glycomantra.com\/sample\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/glycomantra.com\/sample\/wp-json\/wp\/v2\/comments?post=1295"}],"version-history":[{"count":36,"href":"https:\/\/glycomantra.com\/sample\/wp-json\/wp\/v2\/pages\/1295\/revisions"}],"predecessor-version":[{"id":4168,"href":"https:\/\/glycomantra.com\/sample\/wp-json\/wp\/v2\/pages\/1295\/revisions\/4168"}],"wp:attachment":[{"href":"https:\/\/glycomantra.com\/sample\/wp-json\/wp\/v2\/media?parent=1295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}